公开(公告)号：US20190241669A1

公开(公告)日：2019-08-08

申请号：US16384719

申请日：2019-04-15

Applicant: Pfizer Inc.

Inventor： Tracy Chia-Chien KUO ,  Bijan Andre BOLDAJIPOUR ,  Javier Fernando CHAPARRO RIGGERS ,  Philippe DUCHATEAU ,  Roman Ariel GALETTO ,  Alexandre JUILLERAT ,  Thomas Charles PERTEL ,  Arvind RAJPAL ,  Barbra Johnson SASU ,  Cesar Adolfo SOMMER ,  Julien VALTON ,  Thomas John VAN BLARCOM

IPC: C07K16/28 ,  C07K14/705 ,  A61K31/7076 ,  A61K35/17 ,  C12N15/63 ,  C07K14/725 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61K31/7076 ,  A61K35/17 ,  A61K38/00 ,  A61K39/0011 ,  A61K2039/505 ,  A61K2039/5156 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2863 ,  C07K16/2896 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C12N15/63

Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

公开(公告)号：US20230192839A1

公开(公告)日：2023-06-22

申请号：US16500970

申请日：2018-03-29

Applicant: PFIZER INC.

Inventor： Bijan Andre BOLDAJIPOUR ,  Javier Fernando CHAPARRO RIGGERS ,  Xiaodi DENG ,  Kevin Charles LINDQUIST ,  Spencer PARK ,  Edward Derrick PASCUA ,  Thomas John VAN BLARCOM

IPC: C07K16/28 ,  C07K16/00 ,  C12N15/63

CPC classification number: C07K16/28 ,  C07K16/005 ,  C12N15/63 ,  C07K2317/92 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/03

Abstract: Provided herein are antibodies with conditional affinity for an antigen. The affinity of an antibody with conditional affinity for an antigen may be altered by a small molecule agent. Antibodies with conditional affinity may be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.